Cogent Biosciences (COGT) Cash from Investing Activities (2017 - 2026)

Cogent Biosciences' Cash from Investing Activities history runs 9 years deep, the most recent figure standing at -$36.5 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 152.55% year-over-year to -$36.5 million; the TTM figure through Mar 2026 stood at -$505.4 million (down 574.02% YoY), while the FY2025 annual figure was -$399.5 million, down 1143.8% from the prior year.
• Cash from Investing Activities was -$36.5 million for Q1 2026 at Cogent Biosciences, up from -$322.8 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $69.4 million in Q1 2025 to a low of -$322.8 million in Q4 2025.
• Historically, Cash from Investing Activities has averaged -$36.5 million across 5 years, with a median of -$441000.0 in 2022.
• The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities tumbled 12930.44% in 2022, then surged 13679.14% in 2023.
• A 5-year view of Cash from Investing Activities shows it stood at $28.4 million in 2022, then slumped by 63.08% to $10.5 million in 2023, then soared by 487.96% to $61.7 million in 2024, then slumped by 623.37% to -$322.8 million in 2025, then surged by 88.7% to -$36.5 million in 2026.
• The last three Cash from Investing Activities figures came in at -$36.5 million (Q1 2026), -$322.8 million (Q4 2025), and -$155.0 million (Q3 2025), per Business Quant data.